XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations (Tables)
 3 Months Ended
Apr. 03, 2022
Business Acquisition [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block] The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020:
Three Months Ended
April 4, 2021
(In thousands, except per share data)
Pro Forma Statement of Operations Information:
Revenue$1,385,114 
Income from continuing operations$370,624 
Basic earnings per share:
Income from continuing operations$2.94 
Diluted earnings per share:
Income from continuing operations$2.93